These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 21410073

  • 1. Gpc-3 is a notable diagnostic, prognostic and a latent targeted therapy marker in hepatocellular carcinoma.
    Zou ZQ, Ding YP, Long B, Yuh JG, Xu AL, Lang ZW, Zou SY, Liu YD, Ding K, Li YY.
    Hepatogastroenterology; 2010; 57(102-103):1285-90. PubMed ID: 21410073
    [Abstract] [Full Text] [Related]

  • 2. Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma.
    Yorita K, Takahashi N, Takai H, Kato A, Suzuki M, Ishiguro T, Ohtomo T, Nagaike K, Kondo K, Chijiiwa K, Kataoka H.
    Liver Int; 2011 Jan; 31(1):120-31. PubMed ID: 20964802
    [Abstract] [Full Text] [Related]

  • 3. Diagnostic utility of glypican-3 for hepatocellular carcinoma on liver needle biopsy.
    Wang FH, Yip YC, Zhang M, Vong HT, Chan KI, Wai KC, Wen JM.
    J Clin Pathol; 2010 Jul; 63(7):599-603. PubMed ID: 20501450
    [Abstract] [Full Text] [Related]

  • 4. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies.
    Nassar A, Cohen C, Siddiqui MT.
    Diagn Cytopathol; 2009 Sep; 37(9):629-35. PubMed ID: 19405109
    [Abstract] [Full Text] [Related]

  • 5. [Genomic analysis of hepatocellular carcinoma and its application to diagnosis].
    Murakami Y.
    Nihon Rinsho; 2010 Aug; 68 Suppl 8():458-61. PubMed ID: 20979296
    [No Abstract] [Full Text] [Related]

  • 6. Discovery and diagnostic value of a novel oncofetal protein: glypican 3.
    Wang SK, Zynger DL, Hes O, Yang XJ.
    Adv Anat Pathol; 2014 Nov; 21(6):450-60. PubMed ID: 25299314
    [Abstract] [Full Text] [Related]

  • 7. Glypican-3 immunostaining significantly improves histological diagnosis of hepatocellular carcinoma.
    Honsová E, Lodererová A, Franková S, Oliverius M, Trunecka P.
    Cas Lek Cesk; 2011 Nov; 150(1):37-40. PubMed ID: 21400962
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Study on Diagnostic Values of Astrocyte Elevated Gene 1 (AEG-1) and Glypican 3 (GPC-3) in Hepatocellular Carcinoma.
    Cao W, Sharma M, Imam R, Yu J.
    Am J Clin Pathol; 2019 Oct 07; 152(5):647-655. PubMed ID: 31305883
    [Abstract] [Full Text] [Related]

  • 10. Modern diagnosis of hepatocellular carcinoma: Utilization of liver biopsy and genomic markers.
    Marrero JA.
    J Hepatol; 2009 Apr 07; 50(4):659-61. PubMed ID: 19237223
    [No Abstract] [Full Text] [Related]

  • 11. Annexin A2 as a differential diagnostic marker of hepatocellular tumors.
    Longerich T, Haller MT, Mogler C, Aulmann S, Lohmann V, Schirmacher P, Brand K.
    Pathol Res Pract; 2011 Jan 15; 207(1):8-14. PubMed ID: 20971570
    [Abstract] [Full Text] [Related]

  • 12. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy.
    Anatelli F, Chuang ST, Yang XJ, Wang HL.
    Am J Clin Pathol; 2008 Aug 15; 130(2):219-23. PubMed ID: 18628090
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Expression and prognostic role of Spy1 as a novel cell cycle protein in hepatocellular carcinoma.
    Ke Q, Ji J, Cheng C, Zhang Y, Lu M, Wang Y, Zhang L, Li P, Cui X, Chen L, He S, Shen A.
    Exp Mol Pathol; 2009 Dec 15; 87(3):167-72. PubMed ID: 19686732
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prognosis evaluation in alpha-fetoprotein negative hepatocellular carcinoma after hepatectomy: comparison of five staging systems.
    Zhang XF, Qi X, Meng B, Liu C, Yu L, Wang B, Lv Y.
    Eur J Surg Oncol; 2010 Aug 15; 36(8):718-24. PubMed ID: 20538423
    [Abstract] [Full Text] [Related]

  • 17. Osteopontin combined with CD44, a novel prognostic biomarker for patients with hepatocellular carcinoma undergoing curative resection.
    Yang GH, Fan J, Xu Y, Qiu SJ, Yang XR, Shi GM, Wu B, Dai Z, Liu YK, Tang ZY, Zhou J.
    Oncologist; 2008 Nov 15; 13(11):1155-65. PubMed ID: 18997126
    [Abstract] [Full Text] [Related]

  • 18. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance.
    Li J, Wang Y, Yu W, Chen J, Luo J.
    Biochem Biophys Res Commun; 2011 Mar 04; 406(1):70-3. PubMed ID: 21295551
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Characteristics and prognosis of patients in Japan with viral marker-negative hepatocellular carcinoma.
    Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Kanamori A, Yamaguchi A, Isogai M, Kaneoka Y, Washizu J.
    J Gastroenterol Hepatol; 2008 Mar 04; 23(3):459-66. PubMed ID: 17854425
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.